Acrivon Therapeutics Inc. Common Stock (ACRV)

About ACRV

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature c…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

74

Website

acrivon.com/

Fundamentals

1-day range

$2.05$2.19

Market cap

$72.33M

P/E (trailing)

—

P/E (forward)

-1.22

EPS (trailing)

$-2.00

Dividend yield

—

Beta

2.00

Avg. volume

404.8K

Forecasts

6 analyst ratings

Acrivon Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ACRV

  Acrivon Therapeutics Inc. Common Stock

  $2.06

  ▼ 4.19%
  Market cap $72.33MP/E —
  $1.27$3.56
• ELTX

  Elicio Therapeutics Inc. Common Stock

  $2.86

  ▼ 4.67%
  Market cap $72.28MP/E —
  $2.66$16
• SPRO

  Spero Therapeutics Inc. Common Stock

  $1.2

  ▼ 0.83%
  Market cap $73.53MP/E 4.73
  $1.08$3.08
• ACET

  Adicet Bio Inc. Common Stock

  $9.05

  ▲ 0.44%
  Market cap $74.13MP/E —
  $6.01$17.44
• OSTX

  OS Therapies Incorporated Common Stock

  $1.64

  ▼ 2.38%
  Market cap $74.23MP/E —
  $1.15$2.54
• INO

  Inovio Pharmaceuticals Inc. Common Stock

  $1.28

  ▲ 1.59%
  Market cap $69.62MP/E —
  $0.56$2.98
• XBIT

  XBiotech Inc. Common Stock

  $2.27

  ▼ 0.00%
  Market cap $69.51MP/E —
  $2.09$3.59

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate
  benzinga · 8/12/2026
• Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
  Yahoo · 8/12/2026
• Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate
  Benzinga · 8/12/2026
• Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
  Yahoo · 8/5/2026
• Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 Study
  Benzinga · 8/5/2026

• Peter Blume-Jensen · August 25, 2026 · Sale

  14.0K @ $2.21
• Adam D. Levy · August 4, 2026 · Sale

  1.1K @ $1.57
• Mary Miller · July 21, 2026 · Sale

  573 @ $1.76
• Santhosh Palani · June 17, 2026 · Grant

  20.3K
• Derek DiRocco · June 17, 2026 · Grant

  20.3K
• Sharon Shacham · June 17, 2026 · Grant

  20.3K
• Charles M. Baum · June 17, 2026 · Grant

  20.3K
• Michael John Tomsicek · June 17, 2026 · Grant

  20.3K
• RA Capital Healthcare Fund LP · June 17, 2026 · Grant

  20.3K
• Ivana Magovcevic-Liebisch · June 17, 2026 · Grant

  20.3K
• Peter Blume-Jensen · May 21, 2026 · Tax Withholding

  13.7K @ $1.79
• Santhosh Palani · May 18, 2026 · Grant

  9.4K
• Derek DiRocco · May 18, 2026 · Grant

  9.4K
• Katharine Peterson · May 18, 2026 · Grant

  14.2K
• Mary Miller · May 18, 2026 · Grant

  49.8K

Institutional Ownership

March 31, 2026

Total shares held

16.12M

Total value held

$20.98M

Institutional holders

41